Trump Signs Executive Order to Reclassify Cannabis, Shifting US Drug Policy

President Donald Trump has signed an executive order that significantly alters the landscape of US drug policy by expanding access to cannabis. This directive, described by the White House as the most substantial change in decades, instructs the US attorney general to reclassify cannabis from a Schedule 1 narcotic to a Schedule 3 drug. This new classification aligns cannabis with medications such as Tylenol with codeine, reflecting a shift in how the federal government views its medical potential.

While cannabis will remain illegal at the federal level, this reclassification facilitates increased research into its medical benefits. The US Drug Enforcement Agency categorizes Schedule 3 drugs, which also include ketamine and anabolic steroids, as substances with a “moderate to low potential for physical and psychological dependence.”

In remarks made in the Oval Office, Trump emphasized the need for this change, stating that individuals suffering from conditions like cancer and seizure disorders, as well as veterans with service-related injuries, have been “begging” for access to cannabis. He likened cannabis to prescription painkillers, which may have legitimate uses but can also lead to serious harm.

Tax Implications and Legislative Efforts

The new classification brings with it tax benefits for state-authorized cannabis dispensaries, which have been restricted from certain deductions under the current Schedule 1 classification. In addition to the reclassification order, Trump has directed White House officials to collaborate with Congress to allow broader access to cannabidiol (CBD), a compound derived from cannabis known for its potential health benefits. Health officials have been tasked with developing methods to assess the real-world health implications of both cannabis and CBD.

A senior administration official characterized this action as a “commonsense” initiative that will enhance understanding and research of cannabis-related products. Currently, most US states permit cannabis use for medical purposes, and 24 states have legalized its recreational use. Despite this, cannabis has held its Schedule 1 classification since 1971, which designates it as having no accepted medical use and a high potential for abuse.

Trump’s executive order comes on the heels of stalled efforts under the Biden administration, where a proposed reclassification faced significant administrative and legal hurdles.

Reactions from Advocacy Groups and Lawmakers

Advocacy groups have largely welcomed the executive order. Tim Barash, chairman of the Coalition of Cannabis Scheduling Reform, described the decision as a “fundamental shift” in both governmental and societal attitudes towards cannabis. He noted that the change would empower approximately 425,000 individuals working in the US cannabis industry, attracting new talent and investment while positively impacting millions of lives.

However, the decision has faced criticism from some Republican lawmakers. A group of 22 Republican senators expressed concerns in an open letter, arguing that marijuana use might hinder efforts to “re-industrialise America.” They highlighted health risks associated with cannabis, including potential cognitive impairments.

In a separate letter to Attorney General Pam Bondi, nine Republican representatives contended that there is “no adequate science or data” to support the rescheduling of cannabis. They emphasized that while marijuana may differ from more harmful substances like heroin, it still poses a risk for abuse and lacks scientifically supported medical value. They cautioned that reclassification could mislead younger generations into believing cannabis is safe for use.

Public opinion appears to be shifting towards support for cannabis legalization. A Gallup poll released in November 2023 indicated that 64% of Americans favor legalizing marijuana, though support has waned among some Republican demographics.

The executive order represents a pivotal moment in US drug policy and reflects changing attitudes toward cannabis at both the federal and state levels. As the implications of this reclassification unfold, the focus will likely remain on its potential to reshape the medical landscape and influence future legislative developments.